Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Sprint Bioscience

1.53 SEK

-4.09 %

Less than 1K followers

SPRINT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-4.09 %
+116.62 %
+150.00 %
+264.83 %
-1.98 %
-7.59 %
+143.06 %
-75.85 %
-87.01 %

Sprint Bioscience is a research company. The company develops drug candidates that can fight cancer individually or in combination with other drugs. The company has a portfolio of projects that are focused on attacking parts of the processes of cancer cells. The business model is based on a project portfolio and developing projects in parallel in the preclinical phase and then entering into licensing agreements with the global pharmaceutical industry. The company is headquartered in Huddinge.

Read more
Market cap
160.91M SEK
Turnover
1.23M SEK
Revenue
65.64M
EBIT %
-29.97 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11/2
2026

Annual report '25

All
Press releases
ShowingAll content types
Press release12/5/2025, 7:58 AM

Redeye: Sprint Bioscience (Q3 review) - Gilead deal a strong confirmation

Sprint Bioscience
Press release11/27/2025, 1:17 PM

BioStock: Sprint Bioscience: ”We have shown it is possible to make early deals”

Sprint Bioscience
Press release11/27/2025, 1:17 PM

BioStock: Sprint Bioscience: ”We have shown it's possible to make early deals”

Sprint Bioscience

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release11/25/2025, 6:30 AM

Sprint Bioscience delårsrapport för januari – september 2025

Sprint Bioscience
Press release11/24/2025, 2:23 PM

BioStock: Sprint Bioscience säljer cancerprogrammet TREX1 till Gilead

Sprint Bioscience
Press release11/24/2025, 2:23 PM

BioStock: Sprint Bioscience sells cancer program TREX1 to Gilead

Sprint Bioscience
Regulatory press release11/24/2025, 5:08 AM

Sprint Bioscience säljer TREX1-programmet till Gilead

Sprint Bioscience
Regulatory press release11/24/2025, 5:08 AM

Sprint Bioscience sells the TREX1 program to Gilead

Sprint Bioscience
Press release11/19/2025, 7:17 AM

BioStock: Video från Sprint Biosciences presentation vid BioStock Life Science Summit 2025

Sprint Bioscience
Press release11/19/2025, 7:17 AM

BioStock: Video from Sprint Bioscience's presentation at BioStock Life Science Summit 2025

Sprint Bioscience
Press release9/4/2025, 9:05 AM

Redeye: Sprint Bioscience - A clear objective to secure a new partner

Sprint Bioscience
Regulatory press release8/27/2025, 5:30 AM

Sprint Bioscience delårsrapport för januari – juni 2025

Sprint Bioscience
Press release6/26/2025, 2:45 PM

Sprint Biosciences DCPS-data publiceras i Leukemia

Sprint Bioscience
Press release6/26/2025, 2:45 PM

Sprint Bioscience’s DCPS data published in Leukemia

Sprint Bioscience
Regulatory press release6/18/2025, 5:18 PM

Sprint Bioscience samarbetar för att ta MASH-programmet till inflammation

Sprint Bioscience
Regulatory press release6/18/2025, 5:18 PM

Sprint Bioscience collaborates to expand its MASH programme into inflammation

Sprint Bioscience
Press release5/30/2025, 9:37 AM

Redeye: Sprint Bioscience - Increased pressure ahead of the next sprint baton-exchange

Sprint Bioscience
Regulatory press release5/27/2025, 5:30 AM

Sprint Bioscience delårsrapport för januari – mars 2025

Sprint Bioscience
Regulatory press release5/19/2025, 9:00 AM

Sprint Biosciences CFO Niklas Axelsson lämnar bolaget

Sprint Bioscience
Regulatory press release5/13/2025, 2:00 PM

Sprint Biosciences företrädesemission är registrerad – omvandling av BTA till aktier

Sprint Bioscience
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.